ASCO 2026: Key Breast Cancer Abstracts Driving the Future of Precision Oncology
- Home
- asco conference 2026
- breast cancer abstracts asco 2026
Breast Caccer Abstracts | ASCO 2026
ASCO 2026: Key Breast Cancer Abstracts Driving the Future of Precision Oncology
Breast cancer is expected to remain a major focus at the 2026 ASCO Annual Meeting, with presentations centered on precision medicine, antibody-drug conjugates (ADCs), ctDNA/MRD testing, and novel immunotherapy combinations across HR+/HER2−, HER2-positive, and triple-negative breast cancer (TNBC). The meeting is anticipated to highlight the continued shift toward biomarker-driven and personalized treatment strategies, particularly in difficult-to-treat and early-stage settings.
Major Themes and Expected Focus Areas
-
Expansion of ADCs into earlier lines of therapy
-
Advancements in SERDs and endocrine resistance management
-
Increasing adoption of ctDNA and MRD testing for disease monitoring
-
Novel immunotherapy combinations in TNBC
-
AI-driven diagnostics and molecular profiling
-
Personalized treatment approaches based on biomarker stratification
-
Long-term safety and cardiometabolic impact of endocrine therapies.
|
Abstract # |
Session Type |
Company |
Drug Name |
Indication |
Phase |
Key Focus/ Known Data | |
|
502 |
Oral Abstract Session |
|
Giredestrant |
Estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) |
Phase III (lidERA) |
Efficacy and safety of giredestrant results by menopausal status | |
|
LBA1000 |
Oral presentations |
|
TRODELVY + KEYTRUDA |
Previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) |
Phase III (ASCENT-04) |
Primary ASCENT-04 data compare first-line chemo–immunotherapy versus sacituzumab govitecan + pembrolizumab for PD-L1–expressing mTNBC, potentially redefining frontline combination intensity | |
|
1001 |
Oral presentations |
|
Sacituzumab govitecan |
Previously untreated metastatic triple-negative breast cancer (mTNBC) |
Phase III (ASCENT-03) |
Progression-free survival after next line of treatment (PFS2) and subsequent therapies in the ASCENT-03 study | |
|
LBA1007 |
Oral presentations |
|
Camizestrant + CDK 4/6 inhibitors |
HR+/ HER2-advanced breast cancer whose tumours have an emergent ESR1 mutation |
Phase III (SERENA-6) |
SERENA-6 used ctDNA liquid biopsy to detect emergent ESR1 mutations pre-progression and switched aromatase inhibitors to camizestrant while maintaining CDK4/6 inhibition. | |
|
507 |
Oral Abstract Session |
|
Pembrolizumab + chemotherapy |
Stage II–III/high-risk early TNBC populations |
Phase III (KEYNOTE-522) |
Full KEYNOTE-522 data set to redefine treatment standards in early-stage TNBC | |
|
1002 |
Oral Abstract Session |
|
DATROWAY (datopotamab deruxtecan) |
Patients with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitors |
Phase III (TROPION-Breast02) |
Additional efficacy endpoints from the TROPION-Breast02 | |
|
1021 |
Rapid Oral Abstract |
ENHERTU + pertuzumab |
1st-line treatment of patients with HER2-positive metastatic breast cancer |
Phase III (DESTINY-Breast09) |
Exploratory analysis of treatment duration and clinical outcomes by complete response, partial response or stable/progressive disease | ||
|
3088 |
poster presentation |
|
OP-3136 + endocrine therapy |
ER+, HER2− advanced breast cancer |
Phase I |
Presenting preliminary results of Phase I data for OP-3136 | |
|
222; 221 |
Poster Session |
|
Bria-IMT + CPI (Immune checkpoint inhibitor; CPI) |
Advanced metastatic breast cancer |
Phase II |
Survival and quality of life and treatment tolerability of Bria-IMT + CPI at 12 and 24 months | |
|
LBA1018 |
Rapid Oral Presentation |
|
Palbociclib plus Tamoxifen ± goserelin |
Maintenance therapy for HER2+ metastatic breast cancer (MBC) |
Phase III |
Will present final Overall Survival (OS) analysis | |
|
1005 |
Oral Presentation |
TUKYSA (tucatinib) |
First-line maintenance strategy for HER2+ MBC |
Phase III (HER2CLIMB-05) |
Extending potential impact of innovative therapies in earlier lines of treatment | ||
|
2652 |
Poster Session |
|
Bria-IMT |
Advanced metastatic breast cancer |
Phase III |
Monitoring blood-based biomarkers as early predictors of progression-free survival | |
|
3096 |
Poster Session |
|
XOFIGO (Radium-223 dichloride) + paclitaxel |
Bone metastatic breast cancer |
Phase II (ETCTN 10302) |
A randomized trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer | |
|
1098 |
Poster Session |
|
Elacestrant + capivasertib |
ER+/HER2- PI3K/AKT/PTEN- pathway altered metastatic breast cancer |
Phase I/II (ELEVATE) |
Data from the elacestrant + capivasertib regimen of the ELEVATE study will be presented underscoring its potential in combination settings in mBC | |
|
1138 |
Poster Session |
|
Combination of atezolizumab, cobimetinib, and eribulin (ACE) |
Inflammatory breast cancer (IBC) |
Phase Ib/II |
Phase Ib/II ACE analysis identified distinct inflammatory and metabolic response profiles. | |
|
508 |
Rapid Oral Abstract Session |
|
Capecitabine + trastuzumab |
Stage IA HER2-positive breast cancer |
Phase II |
To determine whether treatment with capecitabine and trastuzumab was well tolerated and yielded clinically acceptable outcome | |
|
LBA660 |
Oral Presentation |
|
Anbenitamab plus nab-docetaxel ± carboplatin |
Neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: |
Phase III |
Evaluate the efficacy and safety of anbenitamab + HB1801 ± carboplatin versus trastuzumab plus pertuzumab and docetaxel ± carboplatin as neoadjuvant therapy | |
|
2524 |
Poster Session |
|
IMC-002 |
Advanced triple negative breast cancer (TNBC) |
Phase Ib |
Phase Ib expansion cohort results in TNBC demonstrated safety, efficacy, and soluble biomarker findings | |
Key Companies to Watch at ASCO 2026
AstraZeneca, Daiichi Sankyo, Roche/Genentech, Gilead Sciences, Bayer, Pfizer, Merck and Olema Oncology are expected to present key breast cancer data across ADCs, SERDs, immunotherapy, ctDNA/MRD testing, and precision medicine approaches.
Executive Summary
Breast cancer is expected to remain a major focus at the 2026 ASCO Annual Meeting, with presentations centered on precision medicine, antibody-drug conjugates (ADCs), ctDNA/MRD testing, and novel immunotherapy combinations across HR+/HER2−, HER2-positive, and triple-negative breast cancer (TNBC).